Poolbeg Pharma PLC, up 13% at 4.18 pence, 12-month range 2.25p-8.50p. The clinical stage biopharmaceutical firm, focused on cancer immunotherapy, reports that the European Patent Office has granted a ...

The Guernsey-registered investment fund targets environmental infrastructure, with assets in the UK and Europe. Its shares fell 6.5% to 66.28 pence on Thursday morning in London.

JD Sports said recent indicators have shown "incrementally weaker macroeconomic and consumer external data points in our key markets" while the company is "particularly mindful" of the pressures on ...

Dr Martens declared an interim dividend of 0.85 pence per shape, flat year-on-year. Looking ahead, the company said it is trading in line with expectations. It noted that its sell-side adjusted pretax ...

Berenberg raises Atalaya Mining to 'buy' (hold) - price target 760 (630) pence Comments and questions to [email protected] Copyright 2025 Alliance News Ltd. All Rights Reserved.

The Hertfordshire, England-based maker of components and systems for aerospace & defence, land vehicle, and power & energy customers said group revenue rose 5.9% year-on-year on a constant-currency ...

(Alliance News) - CMC Markets PLC on Thursday raised annual guidance reflecting accelerating momentum, record client cash balances, rising activity levels and stronger performance metrics.

PayPoint noted a 9.6% drop in revenue for the Love2shop segment, which fell to GBP17.0 million from GBP18.8 million. Love2shop's decline was offset by growth in the PayPoint segment. Revenue for the ...

(Alliance News) - Investec PLC and Ltd on Thursday reported a slight decline in interim profit as lower interest rates dented income.

(Alliance News) - Nationwide Building Society on Thursday revealed a fall in mortgage lending after UK homebuyers raced to complete purchases ahead of April's stamp duty deadline, but net interest ...

(Alliance News) - AstraZeneca PLC on Thursday said US regulators have approved its drug Koselugo for use in adults with neurofibromatosis type 1, expanding access to a treatment already used in ...